Key Highlights

● Alterity Therapeutics scheduled its Annual General Meeting for 11:00 a.m. AEDT on Friday, November 20, 2026.

● The filing set October 2, 2026 at 5:00 p.m. AEST as the deadline for shareholders to nominate a director.

● As a dual-listed foreign private issuer, Alterity furnished the notice via Form 6-K under ASX Listing Rule 3.13.1.

● A separate, more detailed Notice of Meeting with the full agenda will follow ahead of the November gathering.

Alterity Therapeutics Limited (NASDAQ:ATHE) disclosed in a Form 6-K filed September 25, 2026 that it has scheduled its annual general meeting for 11:00 a.m. Australian Eastern Daylight Time on Friday, November 20, 2026. The filing, made under ASX Listing Rule 3.13.1 and furnished to the SEC as an exhibit, also sets Friday, October 2, 2026 at 5:00 p.m. Australian Eastern Standard Time as the deadline for shareholders wishing to nominate a director to submit their nomination.

A Dual-Listed Company's Routine Notice

Alterity is incorporated and headquartered in Australia, at Level 15, 500 Collins Street in Melbourne, and its shares trade on both the Australian Securities Exchange under the ticker ATH and on Nasdaq under the ticker ATHE. Because Alterity is a foreign private issuer for SEC purposes, it reports material announcements through Form 6-K rather than a domestic 8-K, and this filing furnishes an ASX-format announcement to satisfy that requirement. The announcement notes it is made in accordance with ASX Listing Rule 3.13.1, the Australian rule requiring listed companies to give advance notice of their annual meeting date and, separately, the deadline for director nominations.

The Nomination Process

Individuals interested in standing for election to Alterity's board must submit a written nomination to the company's registered office in Melbourne by the October 2, 2026 deadline. The filing does not specify how many board seats are up for election at this year's meeting, whether any incumbent directors are retiring, or whether the board has already identified its own slate of nominees to present alongside any shareholder-submitted candidates. Advance nomination deadlines of this kind are a routine feature of Australian corporate governance practice, giving the company time to vet candidates before finalizing its meeting materials.

What Shareholders Will Receive Next

The filing states that shareholders will receive a separate, more detailed Notice of Meeting ahead of the November 20 gathering, to be made available both through the ASX platform and on Alterity's own website. That forthcoming notice would typically include the full agenda, including any resolutions on executive compensation, director elections, or other matters requiring a Shareholder vote, none of which are detailed in this preliminary date-setting announcement.

Limited Business Detail in This Filing

This 6-K is narrowly focused on meeting logistics and does not describe Alterity's business operations, pipeline, or recent financial results. The filing was signed by Julian Babarczy, identified as Chairman, and is incorporated by reference into the company's other SEC registration statements, including its Form S-8 and Form F-3 filings, a standard mechanism that keeps those documents current with newly furnished information.

What the Filing Does Not Say

Investors will not find the meeting's proposed resolutions, board nominee names, executive compensation matters, or Record Date for voting eligibility in this filing. Those details are deferred to the forthcoming full Notice of Meeting referenced in the announcement, meaning shareholders seeking to understand what will actually be voted on in November must wait for that separate document. The filing also does not describe Alterity's clinical programs, cash position, or any recent corporate developments.

Key Dates for Shareholders to Track

Shareholders wishing to nominate a director must act before the October 2, 2026 deadline at 5:00 p.m. Australian Eastern Standard Time. The full Notice of Meeting is expected before the November 20, 2026 annual general meeting, and that document should disclose the specific resolutions shareholders will be asked to approve, along with a record date for determining eligibility to vote.